Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

RAPPRapport Therapeutics, Inc.

Nasdaq · CIK 0002012593
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts192

Identity from submissions API

NameRapport Therapeutics, Inc.
CIK0002012593
TickersRAPP
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN880724208
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone857-321-8020
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Rapport Therapeutics, Inc. (2024-03-27T04:00:00.000Z → 2026-11-16T05:00:00.000Z)
Business address
99 HIGH STREET
SUITE 2100
BOSTON
MA
02110
MA
Mailing address
99 HIGH STREET
SUITE 2100
BOSTON
MA
02110
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

254 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005299 005-94532 261559155 34 9666
2026-11-04 10-Q 10-Q 0001193125-26-446217 001-42121 261520054 34 10565285 1 1
2026-11-04 8-K 8-K 2.02,9.01 0001193125-26-446202 001-42121 261520031 34 394501 1 1
2026-11-03 4 4 0001193125-26-445438 17405
2026-10-30 4 OWNERSHIP DOCUMENT 0001104659-26-120789 13062
2026-10-30 8-K 8-K 1.01,2.02,2.03,3.02,9.01 0001193125-26-441851 001-42121 261508919 34 2668266 1 1
2026-10-30 424B5 424B5 0001193125-26-439869 333-294170 261504392 33 1460174 1 1
2026-10-30 424B5 424B5 0001193125-26-439863 333-294170 261504386 33 967637 1 1
2026-10-29 305B2 305B2 0001193125-26-437789 333-294170 261501772 33 162890
2026-10-28 FWP FWP 0001193125-26-435057 333-294170 261492355 34 96049
2026-10-28 FWP FWP 0001193125-26-435030 333-294170 261492297 34 28716
2026-10-28 FWP FWP 0001193125-26-434838 333-294170 261492192 34 110836
2026-10-28 FWP FWP 0001193125-26-434642 333-294170 261492069 34 26224
2026-10-27 424B5 424B5 0001193125-26-434382 333-294170 261491246 33 1321426
2026-10-27 424B5 424B5 0001193125-26-434371 333-294170 261491220 33 738481
2026-10-23 4 4 0001193125-26-430504 6710
2026-10-23 4 4 0001193125-26-430397 5043
2026-10-22 4 4 0001193125-26-429075 4638
2026-10-22 4 4 0001193125-26-429074 4470
2026-10-22 4 4 0001193125-26-429073 6006
2026-10-22 4 4 0001193125-26-429071 7162
2026-10-21 4 4 0001193125-26-428018 4522
2026-10-20 8-K 8-K 7.01,8.01,9.01 0001193125-26-425647 001-42121 261470424 34 11096429 1 1
2026-10-08 4 4 0001193125-26-417919 8634
2026-10-06 144 xsl144X01/primary_doc.xml 0001958244-26-000649 001-42121 261445084 33 14238
2026-10-01 4 4 0001193125-26-410734 7210
2026-09-30 144 xsl144X01/primary_doc.xml 0001950047-26-009884 001-42121 261427389 33 4752
2026-09-24 4 4 0001193125-26-401017 10037
2026-09-09 4 4 0001193125-26-386436 8634
2026-08-26 4 4 0001193125-26-368285 6711
2026-08-26 4 4 0001193125-26-368244 9151
2026-08-25 144 xsl144X01/primary_doc.xml 0001950047-26-008670 001-42121 261316188 33 6376
2026-08-24 144 xsl144X01/primary_doc.xml 0001950047-26-008594 001-42121 261310897 33 5652
2026-08-20 4 4 0001193125-26-359189 4784
2026-08-19 144 xsl144X01/primary_doc.xml 0001950047-26-008426 001-42121 261295851 33 4939
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-352285 005-94532 261281784 34 15367
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-003693 005-94532 261279717 34 9631
2026-08-12 4 4 0001193125-26-346995 14408
2026-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001562230-26-000114 005-94532 261265786 34 7681
2026-08-05 10-Q 10-Q 0001193125-26-333862 001-42121 261241351 34 9774140 1 1
2026-08-05 8-K 8-K 2.02,9.01 0001193125-26-333853 001-42121 261241337 34 464548 1 1
2026-07-29 4 4 0001193125-26-323637 9180
2026-07-15 4 4 0001193125-26-304786 9699
2026-07-01 4 4 0001193125-26-292546 11058
2026-07-01 4 4 0001193125-26-292519 9699
2026-06-30 144 xsl144X01/primary_doc.xml 0001950047-26-006648 001-42121 261140977 33 4752
2026-06-29 144 xsl144X01/primary_doc.xml 0001958244-26-000411 001-42121 261136453 33 5333
2026-06-10 4 4 0001193125-26-266155 5360
2026-06-10 4 4 0001193125-26-266147 5403
2026-06-10 4 4 0001193125-26-266129 5412
2026-06-10 4 4 0001193125-26-266099 5413
2026-06-10 4 4 0001193125-26-266095 5367
2026-06-10 4 4 0001193125-26-266090 5413
2026-06-10 4 4 0001193125-26-266086 5414
2026-06-10 4 4 0001193125-26-266080 5426
2026-06-10 8-K 8-K 5.07 0001193125-26-265841 001-42121 261079783 34 183108 1 1
2026-05-28 4 4 0001193125-26-245259 15713
2026-05-27 144 xsl144X01/primary_doc.xml 0001974078-26-000199 001-42121 261022450 33 7115
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-002222 005-94532 26985283 34 9660
2026-05-13 4 4 0001193125-26-222185 15709
2026-05-11 4 4 0001193125-26-217092 17674
2026-05-11 144 xsl144X01/primary_doc.xml 0001974078-26-000178 001-42121 26963592 33 6585
2026-05-08 144 xsl144X01/primary_doc.xml 0001974078-26-000173 001-42121 26959409 33 5948
2026-05-07 144 xsl144X01/primary_doc.xml 0001974078-26-000168 001-42121 26954400 33 5299
2026-05-07 10-Q 10-Q 0001193125-26-210355 001-42121 26950887 34 8982683 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-210324 001-42121 26950843 34 474365 1 1
2026-04-23 ARS ARS 0001193125-26-171842 001-42121 26885559 34 8388555
2026-04-23 DEFA14A DEFA14A 0001193125-26-171836 001-42121 26885543 34 243029
2026-04-23 DEF 14A DEF 14A 0001193125-26-171828 001-42121 26885537 34 954693 1 1
2026-04-21 4 4 0001193125-26-167636 15708
2026-04-21 4 4 0001193125-26-167091 5303
2026-04-21 8-K 8-K 7.01,8.01 0001193125-26-167078 001-42121 26880231 34 26510846 1 1
2026-04-17 144 xsl144X01/primary_doc.xml 0001950047-26-003609 001-42121 26872148 33 8544
2026-04-17 144 xsl144X01/primary_doc.xml 0001974078-26-000144 001-42121 26871912 33 4680
2026-04-14 4 4 0001193125-26-154908 8630
2026-04-13 144 xsl144X01/primary_doc.xml 0001950047-26-003401 001-42121 26858221 33 7099
2026-04-10 144 xsl144X01/primary_doc.xml 0001950047-26-003382 001-42121 26855376 33 6383
2026-04-09 4 4 0001193125-26-149725 4783
2026-04-08 144 xsl144X01/primary_doc.xml 0001950047-26-003340 001-42121 26849198 33 5494
2026-03-31 4 4 0001193125-26-134684 7209
2026-03-30 144 xsl144X01/primary_doc.xml 0001950047-26-003074 001-42121 26813291 33 5443
2026-03-26 4 4 0001193125-26-126410 5303
2026-03-25 144 xsl144X01/primary_doc.xml 0001950047-26-002990 001-42121 26792737 33 5641
2026-03-10 S-3ASR S-3ASR 0001193125-26-099421 333-294170 26737299 33 1570834 1 1
2026-03-10 S-8 S-8 0001193125-26-099377 333-294169 26737244 33 302942 1 1
2026-03-10 10-K 10-K 0001193125-26-099360 001-42121 26737218 34 23154864 1 1
2026-03-10 8-K 8-K 2.02,9.01 0001193125-26-099336 001-42121 26737170 34 537846 1 1
2026-03-09 4 4 0001193125-26-098488 5091
2026-03-05 144 xsl144X01/primary_doc.xml 0001193125-26-094361 001-42121 26727710 33 4418
2026-02-19 4 4 0001193125-26-059886 13027
2026-02-19 4 4 0001193125-26-059883 12957
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-26-001034 005-94532 26640026 34 9576
2026-02-04 4 4 0001193125-26-037618 5337
2026-02-04 4 4 0001193125-26-037603 5335
2026-02-04 4 4 0001193125-26-037587 5319
2026-02-04 4 4 0001193125-26-037581 5347
2026-02-04 4 4 0001193125-26-037570 5322
2026-02-04 4 4 0001193125-26-037529 5330
2026-01-22 4 4 0001193125-26-019820 8995
2026-01-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-26-000711 005-94532 26545874 34 10874
2026-01-16 4 4 0001193125-26-015350 6544
2026-01-15 144 xsl144X01/primary_doc.xml 0001950047-26-000482 001-42121 26536614 33 7000
2026-01-07 8-K 8-K 8.01,9.01 0001193125-26-005499 001-42121 26514100 34 195676 1 1
2026-01-07 424B5 424B5 0001193125-26-005482 333-288444 26514073 33 482964
2026-01-07 8-K 8-K 7.01,8.01,9.01 0001193125-26-005446 001-42121 26513974 34 25586785 1 1
2026-01-05 4 4 0001193125-26-002470 6855
2026-01-05 4 4 0001193125-26-002469 6565
2026-01-02 144 xsl144X01/primary_doc.xml 0001193125-26-001213 001-42121 26503624 33 6248
2026-01-02 144 xsl144X01/primary_doc.xml 0001193125-26-001211 001-42121 26503615 33 4409
2025-12-18 4 4 0001193125-25-324826 17059
2025-12-17 144 xsl144X01/primary_doc.xml 0001950047-25-010475 001-42121 251579643 33 7731
2025-12-17 144 xsl144X01/primary_doc.xml 0001950047-25-010465 001-42121 251579604 33 7708
2025-12-16 4 4 0001193125-25-321142 7064
2025-12-01 4 4 0001193125-25-303910 8945
2025-11-18 4 4 0001193125-25-286218 13028
2025-11-18 4 4 0001193125-25-286212 7065
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-004952 005-94532 251483868 34 10414
2025-11-06 10-Q 10-Q 0001193125-25-268096 001-42121 251456163 34 10330475 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-268072 001-42121 251456128 34 478436 1 1
2025-10-22 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000904454-25-000502 005-94532 251410807 34 9203
2025-10-16 4 4 0001193125-25-241475 7065
2025-10-16 4 4 0001193125-25-241472 13025
2025-10-15 144 xsl144X01/primary_doc.xml 0001950047-25-007977 001-42121 251395089 33 6305
2025-09-19 4 4 0001193125-25-209062 13029
2025-09-18 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001104659-25-091350 005-94532 251324444 34 63215
2025-09-17 144 xsl144X01/primary_doc.xml 0001950047-25-007282 001-42121 251320385 33 4817
2025-09-17 144 xsl144X01/primary_doc.xml 0001950047-25-007277 001-42121 251320366 33 4849
2025-09-17 4 4 0001193125-25-206203 7065
2025-09-15 4 4 0001193125-25-203540 4895
2025-09-15 4 4 0001193125-25-203537 7385
2025-09-11 4 4 0000950170-25-114325 4331
2025-09-10 8-K 8-K 1.01,9.01 0001193125-25-200205 001-42121 251306643 34 446511 1 1
2025-09-10 424B5 424B5 0001193125-25-200200 333-288444 251306627 33 779341
2025-09-10 4 4 0001839046-25-000004 8427
2025-09-08 424B5 424B5 0001193125-25-198453 333-288444 251300843 33 799972
2025-09-08 144 xsl144X01/primary_doc.xml 0001950047-25-006846 001-42121 251300312 33 4991
2025-09-08 8-K 8-K 8.01,9.01 0001193125-25-198322 001-42121 251299990 34 142831 1 1
2025-09-08 8-K 8-K 7.01,8.01,9.01 0001193125-25-197610 001-42121 251298457 34 10801278 1 1
2025-08-18 4 4 0000950170-25-109838 7062
2025-08-07 10-Q 10-Q 0000950170-25-104565 001-42121 251191599 34 10225835 1 1
2025-08-07 8-K 8-K 2.02,7.01,9.01 0000950170-25-104557 001-42121 251191574 34 19325407 1 1
2025-07-16 4 4 0000950170-25-096268 5142
2025-07-09 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002211 333-288445 251114725 33 1748
2025-07-09 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002210 333-288444 251114724 33 1748
2025-07-07 CORRESP filename1.htm 0001193125-25-156166 6478
2025-07-07 CORRESP filename1.htm 0001193125-25-156162 6388
2025-07-07 UPLOAD filename1.pdf 0000000000-25-007103 333-288445 40079
2025-07-07 UPLOAD filename1.pdf 0000000000-25-007101 333-288444 40084
2025-07-01 S-3 S-3 0001193125-25-153417 333-288445 251094139 33 279140
2025-07-01 S-3 S-3 0001193125-25-153415 333-288444 251094137 33 1368766
2025-06-18 8-K 8-K 5.07 0000950170-25-087921 001-42121 251057344 34 182694 1 1
2025-06-18 4 4 0000950170-25-087904 5289
2025-06-18 4 4 0000950170-25-087903 5277
2025-06-18 4 4 0000950170-25-087902 5223
2025-06-18 4 4 0000950170-25-087901 5230
2025-06-18 4 4 0000950170-25-087900 5266
2025-06-18 4 4 0000950170-25-087899 5299
2025-06-18 4 4 0000950170-25-087898 5275
2025-06-18 4 4 0000950170-25-087897 5141
2025-06-18 4 4 0000950170-25-087896 5272
2025-06-16 144 xsl144X01/primary_doc.xml 0001950047-25-004362 001-42121 251050440 33 6189
2025-06-02 8-K 8-K 7.01,8.01,9.01 0000950170-25-080247 001-42121 251014982 34 27218937 1 1
2025-05-19 4 4 0000950170-25-074409 5152
2025-05-08 10-Q 10-Q 0000950170-25-066393 001-42121 25923886 34 9574228 1 1
2025-05-08 8-K 8-K 2.02,9.01 0000950170-25-066376 001-42121 25923837 34 501038 1 1
2025-04-24 ARS ARS 0001193125-25-092144 001-42121 25863454 34 14600093
2025-04-24 DEFA14A DEFA14A 0001193125-25-092139 001-42121 25863446 34 106831
2025-04-24 DEF 14A DEF 14A 0001193125-25-092133 001-42121 25863439 34 1085642 1 1
2025-04-16 4 4 0000950170-25-054819 5153
2025-04-03 4 4 0000950170-25-050557 5394
2025-03-17 4 4 0000950170-25-040447 5162
2025-03-14 144 xsl144X01/primary_doc.xml 0001950047-25-001860 001-42121 25740292 33 4765
2025-03-13 4 4 0000950170-25-038878 5769
2025-03-13 4 4 0000950170-25-038855 4916
2025-03-11 S-8 S-8 0000950170-25-036832 333-285697 25725881 33 303465 1 1
2025-03-11 10-K 10-K 0000950170-25-036828 001-42121 25725859 34 30337088 1 1
2025-03-11 8-K 8-K 2.02,9.01 0000950170-25-036822 001-42121 25725845 34 568639 1 1
2025-03-05 4 4 0000950170-25-033797 4930
2025-03-05 3 3 0000950170-25-033796 14610
2025-03-03 8-K 8-K 7.01,8.01,9.01 0001193125-25-043405 001-42121 25693762 34 16865478 1 1
2025-02-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-019904 005-94532 25620451 34 15159
2025-02-04 4 4 0000950170-25-013754 5340
2025-02-04 4 4 0000950170-25-013753 5368
2025-02-04 4 4 0000950170-25-013752 5343
2025-02-04 4 4 0000950170-25-013751 5356
2025-02-04 4 4 0000950170-25-013750 5351
2025-01-10 8-K 8-K 7.01,8.01,9.01 0001193125-25-004045 001-42121 25520254 34 199186 1 1
2024-11-14 SC 13G ARCH VENTURE FUND XII, L.P. - RAPPORT THERAPEUTICS, INC. -- SCH 13G 0001072613-24-000885 005-94532 241464248 34 231976
2024-11-14 SC 13G/A cormorant-rapp093024a1.htm 0001172661-24-005064 005-94532 241460814 34 86364
2024-11-13 SC 13G SEC SCHEDULE 13G 0001562230-24-000082 005-94532 241452622 34 18289
2024-11-12 SC 13G/A filing.txt 0000315066-24-002916 005-94532 241445000 34 8254
2024-11-07 4 4 0000950170-24-123611 5339
2024-11-07 4 4 0000950170-24-123610 5328
2024-11-07 4 4 0000950170-24-123607 5334
2024-11-07 4 4 0000950170-24-123600 5409
2024-11-07 3 3 0000950170-24-123598 17450
2024-11-07 3 3 0000950170-24-123593 17457
2024-11-07 3 3 0000950170-24-123588 17912
2024-11-07 3 3 0000950170-24-123585 18874
2024-11-07 10-Q 10-Q 0000950170-24-122801 001-42121 241433182 34 8974220 1 1
2024-11-07 8-K 8-K 2.02,9.01 0000950170-24-122792 001-42121 241433146 34 375082 1 1
2024-10-18 SC 13G s13g_093024-rapportthera.htm 0000904454-24-000538 005-94532 241381506 34 51920
2024-08-08 10-Q 10-Q 0000950170-24-093334 001-42121 241186089 34 9118562 1 1
2024-08-08 8-K 8-K 2.02,9.01 0000950170-24-093321 001-42121 241186042 34 457211 1 1
2024-07-26 SEC STAFF LETTER filename1.pdf 9999999997-24-003356 63771
2024-07-10 SC 13G filing.txt 0000315066-24-001831 005-94532 241108969 34 8033
2024-07-03 4 OWNERSHIP DOCUMENT 0001104659-24-077868 30902
2024-06-24 SC 13G/A RAPPORT_V2.txt 0000769993-24-000280 005-94532 241066004 34 49167
2024-06-21 SC 13G RAPPORT.txt 0000769993-24-000277 005-94532 241061157 34 48973
2024-06-20 SC 13G sc13g.htm 0000929638-24-002235 005-94532 241056124 34 183684
2024-06-14 SC 13D SC 13D 0001104659-24-071732 005-94532 241044565 34 143029
2024-06-10 4 4 0000950170-24-071543 19831
2024-06-10 4 4 0000950170-24-071541 5393
2024-06-10 4 4 0000950170-24-071540 5375
2024-06-10 4 4 0000950170-24-071539 5384
2024-06-10 4 4 0000950170-24-071538 5409
2024-06-10 4 4 0000950170-24-071537 23404
2024-06-10 4 4 0000950170-24-071533 5400
2024-06-10 4 4 0000950170-24-071532 18619
2024-06-10 4 4 0000950170-24-071527 5399
2024-06-10 8-K 8-K 1.01,3.02,5.03,9.01 0001193125-24-158327 001-42121 241032748 34 430460
2024-06-07 S-8 S-8 0001193125-24-157474 333-280058 241030353 33 90040
2024-06-07 424B4 424B4 0001193125-24-157358 333-279486 241029553 33 4530313
2024-06-06 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2024-06-06 16:00:00 9999999995-24-001768 333-279486 241027125 33 1765
2024-06-06 3 3 0000950170-24-070115 14545
2024-06-06 3 3 0000950170-24-070095 16183
2024-06-06 3 3 0000950170-24-070092 17898
2024-06-06 3 3 0000950170-24-070091 14476
2024-06-06 3 3 0000950170-24-070086 17163
2024-06-06 3 3 0000950170-24-070084 16975
2024-06-06 3 3 0000950170-24-070083 19093
2024-06-06 3 3 0000950170-24-070078 17837
2024-06-06 3 3 0000950170-24-070077 17875
2024-06-06 3 3 0000950170-24-070076 15741
2024-06-06 3 3 0000950170-24-070071 15789
2024-06-06 3 3 0000950170-24-070069 17726
2024-06-06 3 3 0000950170-24-070065 19906
2024-06-06 3 3 0000950170-24-070063 17158
2024-06-06 CERT 8A_Cert_RAPP.pdf 0001354457-24-000394 001-42121 241024636 34 213202
2024-06-04 8-A12B 8-A12B 0001193125-24-154251 001-42121 241018058 34 14848
2024-06-04 CORRESP filename1.htm 0001193125-24-154245 10904
2024-06-04 CORRESP filename1.htm 0001193125-24-154232 6156
2024-06-03 CORRESP filename1.htm 0001193125-24-152304 23200
2024-06-03 S-1/A S-1/A 0001193125-24-152294 333-279486 241011898 33 5774902
2024-05-29 CORRESP filename1.htm 0001193125-24-149345 82411
2024-05-24 UPLOAD filename1.pdf 0000000000-24-006054 377-07153 43249
2024-05-17 CORRESP filename1.htm 0001193125-24-141723 31329
2024-05-17 S-1 S-1 0001193125-24-141704 333-279486 24959463 33 6842884
2024-05-13 UPLOAD filename1.pdf 0000000000-24-005439 377-07153 44954
2024-05-03 SEC STAFF LETTER filename1.pdf 9999999997-24-002569 65186
2024-04-29 DRSLTR filename1.htm 0000950123-24-003595 42734
2024-04-29 DRS/A filename1.htm 0000950123-24-003594 377-07153 24888066 33 4724117
2024-04-24 UPLOAD filename1.pdf 0000000000-24-004587 377-07153 52570
2024-03-27 DRS filename1.htm 0000950123-24-003008 377-07153 24790880 33 4590492

Latest XBRL company facts

One latest value per concept from companyfacts (192 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 59.28M 2026-11-02 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
dei EntityPublicFloat Entity Public Float USD 275.84M 2025-06-30 2025 FY 10-K 2026-03-10 0001193125-26-099360
ffd NetFeeAmt NetFeeAmt USD 20,010 2026-10-30 424B5 2026-10-30 0001193125-26-439863
ffd TtlFeeAmt TtlFeeAmt USD 20,010 2026-10-30 424B5 2026-10-30 0001193125-26-439863
ffd TtlOfferingAmt TtlOfferingAmt USD 230.00M 2026-10-30 424B5 2026-10-30 0001193125-26-439863
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-10-30 424B5 2026-10-30 0001193125-26-439863
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-10-30 424B5 2026-10-30 0001193125-26-439863
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.72M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 171,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 370,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 16.26M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.79M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 2.12M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -2.12M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 745.19M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 7.63M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 21.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 5.61M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap Assets Assets USD 418.56M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AssetsCurrent Assets, Current USD 407.38M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 2.12M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 322.39M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 228.31M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 320.27M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 74.75M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 395.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 74.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 22.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 48.09M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 48.09M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap CommonStockValue Common Stock, Value, Issued USD 48,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -119.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 22.15M 2024-06-07 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap DeferredFederalStateAndLocalTaxExpenseBenefit Deferred Federal, State and Local, Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 16.80M 2024-06-30 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 2.54M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 500,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction Deferred Tax Assets, Deferred Gain on Sale Leaseback Transaction USD 2.81M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 62.00M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 34.01M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 10.20M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 10.59M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other USD 20,000 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 1.79M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 1.63M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 59.46M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap Depreciation Depreciation USD 600,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 637,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap Dividends Dividends USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268096
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -2.46 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -2.46 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.225 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.006 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0.036 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.017 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 5.65M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 30.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -78.31M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 25.13M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -23.41M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 684,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 9,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 4.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -2.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 171,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 4.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -344,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 3.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 12.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap LeaseCost Lease, Cost USD 2.81M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 13.41M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 821,000 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 3.48M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 879,000 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 2.59M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 2.86M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 2.79M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 1.93M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap Liabilities Liabilities USD 27.37M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 418.56M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap LiabilitiesCurrent Liabilities, Current USD 20.30M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap LossContingencyAccrualAtCarryingValue Loss Contingency Accrual USD 0 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap NetAssetValuePerShare Net Asset Value Per Share USD/shares 1 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 3.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 114.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -96.15M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -116.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -116.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Noncash or Part Noncash Acquisition, Fixed Assets Acquired USD 11,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 12.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OciEquityMethodInvestmentAfterTaxParent OciEquityMethodInvestmentAfterTaxParent USD -2.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingExpenses Operating Expenses USD 149.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -129.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 11.48M 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 2.33M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 7.07M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.21M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 8.13M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 1.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.072 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 214,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 1.09M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -2.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 453,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 58,000 2023-01-01 2023-06-30 2024 Q2 10-Q 2024-08-08 0000950170-24-093334
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 84.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 164,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PreferredStockConvertibleSharesIssuable PreferredStockConvertibleSharesIssuable shares 22.15M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap PreferredStockDividendRatePercentage Preferred Stock, Dividend Rate, Percentage pure 0.08 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 12.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 269.40M 2025-09-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 54,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 63.91M 2024-01-01 2024-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-268096
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 188.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 401,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProceedsFromSaleOfShortTermInvestments Proceeds from Sale of Short-term Investments USD 10.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 4.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -116.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 4.08M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 1.96M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 118.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 105,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -351.94M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 20.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 30.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 21.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price USD/shares 0.74 2023-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.903 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.823 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.044 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 71.01M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 3.34M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 12.34 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 201,239 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 135.18M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 7.95M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 16.72 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 135.18M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 7.95M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 16.72 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 11.36 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 21.27 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 28.92 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShortTermInvestments Short-term Investments USD 320.27M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 66,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 391.19M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.117 2024-05-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 361,827 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments USD 7.34M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 269.44M 2025-07-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 54,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-11 0000950170-25-036828
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 1.71M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 5,000 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 234.74M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 250.18M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 189.61M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 189.61M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 189.61M 2024-03-31 2025 Q1 10-Q 2025-05-08 0000950170-25-066393
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD -29.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap VariableLeaseCost Variable Lease, Cost USD 54,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-10 0001193125-26-099360
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 47.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 47.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001193125-26-446217

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →